On November 26, 2024, Saniona, a clinical-stage biopharmaceutical company, announced a partnership with Acadia Pharmaceuticals (Acadia) for the development and commercialization of SAN711 in neurological diseases. Saniona will receive up to $610 million, including a $28 million upfront payment and up to $582 million in development, regulatory, and commercial milestone payments, along with tiered royalties from mid-single digits to low double digits on global net sales of SAN711. In addition, Acadia will provide financial support for Saniona’s ongoing Phase 1 clinical study and preparation for the Phase 2 clinical study.

Wilson Sonsini Goodrich & Rosati represented Saniona in the transaction. The Wilson Sonsini team includes:

Technology Transactions
Colin Bosch
Farah Gerdes

Antitrust
Jindrich Kloub
Jeff Bank

Tax
Myra Sutanto Shen
Beau Brawner

For more information, please see Saniona's press release.